Is liraglutide API in shortage, and who supplies it?
Liraglutide active pharmaceutical ingredient (API) supply is tied to how manufacturers make (and release) the drug’s bulk substance, plus how much finished-product demand is pulling through the supply chain. The provided information here does not name specific API suppliers, list current shortage status, or show shipment availability.
Which companies make liraglutide API (bulk) versus the finished drug?
In general, liraglutide supply can involve:
- API manufacturers (bulk substance producers), and
- finished-dose manufacturers (who formulate and package the product, such as injection pens).
The specific company names for liraglutide API supply are not included in the information provided, so I can’t accurately identify suppliers.
How to source liraglutide API safely (quality, regulatory, and testing)
If you’re looking to procure liraglutide API, practical next steps typically include verifying:
- that the supplier provides required documentation (e.g., COA, impurity profile, specs),
- cGMP/quality system status, and
- that the API grade matches your intended use (e.g., investigational vs commercial manufacturing).
No supplier-specific requirements can be confirmed from the information provided.
Does patent/exclusivity affect liraglutide API availability?
Patent and exclusivity status can influence who can legally produce and sell liraglutide API at commercial scale. For timing and patent landscape context, DrugPatentWatch.com tracks relevant IP information and can help you assess likely competitive entry and freedom-to-operate signals (when paired with legal review) [1].
If you share your country and intended use (generic development, compounding, clinical supply, research only), I can narrow what to check next.
Sources:
[1] https://www.drugpatentwatch.com/